Charles Schwab
ARTV icon

Charles Schwab’s Artiva Biotherapeutics ARTV Stock Holding History

Charles Schwab’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Buy
+11,896
New +$108K ﹤0.01% 3404
2025
Q2 		– Sell
-54,881
Closed -$165K – 3604
2025
Q1 		$165K Buy
54,881
+11,355
+26% +$61.3K ﹤0.01% 3279
2024
Q4 		$439K Buy
43,526
+3,233
+8% +$38.8K ﹤0.01% 3184
2024
Q3 		$623K Buy
+40,293
New +$467K ﹤0.01% 3082

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Charles Schwab's ARTV Position: Q2 2026 in Review

Charles Schwab opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 11,896 shares worth $115K. The stake represents ﹤0.01% of the portfolio and ranks #3404 among its holdings. This is a return to the name: Charles Schwab previously reported a position in ARTV as recently as Q1 2025.

Charles Schwab first reported a position in ARTV in Q3 2024 and has held it in 4 quarters since. The position peaked at $623K in Q3 2024. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Charles Schwab held 11,896 shares of Artiva Biotherapeutics worth $115K as of Q2 2026.
  • Artiva Biotherapeutics was a new Charles Schwab position in Q2 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3404 holding.
  • Charles Schwab first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 4 quarters since.
  • Charles Schwab's Artiva Biotherapeutics position peaked at $623K in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.